Diabetes Mellitus and Myocardial Mitochondrial Dysfunction: Bench to Bedside

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 551-561

  König, Alexandra ^a   Bode, Christoph ^a   Bugger, Heiko ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antioxidants; Diabetes; Diabetic cardiomyopathy; Metabolic therapy; Mitochondria

Indexed keywords

ALPHA TOCOPHEROL; CREATINE PHOSPHATE; FENOFIBRATE; GLITAZONE DERIVATIVE; GLUTATHIONE; ISOCITRATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RESVERATROL; ROSIGLITAZONE; TEMPOL; UBIQUINONE;

BODY MASS; CALORIC RESTRICTION; CYTOSOL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DELIVERY SYSTEM; ENERGY METABOLISM; FLUID RETENTION; GENE OVEREXPRESSION; GENE TARGETING; GLUCOSE TOLERANCE; HEART CYCLE; HEART DISEASE; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE REPERFUSION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID PEROXIDATION; MITOCHONDRIAL RESPIRATION; NITROSYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; STREPTOZOCIN DIABETES;

ANTIOXIDANTS; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MYOCARDIUM; OXIDATIVE STRESS; RISK ASSESSMENT;

EID: 84866605658     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.001     Document Type: Review

References (106)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035.
2. Poornima I.G., Parikh P., Shannon R.P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006, 98:596.
3. Aboukhoudir F., Rekik S. Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. Int J Cardiovasc Imaging 2011, [Epub ahead of print].
4. Devereux R.B., Roman M.J., Paranicas M., et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000, 101:2271.
5. Fang Z.Y., Najos-Valencia O., Leano R., et al. Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. J Am Coll Cardiol 2003, 42:446.
6. Poirier P., Bogaty P., Garneau C., et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001, 24:5.
7. An D., Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006, 291:H1489.
8. Boudina S., Abel E.D. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010, 11:31.
9. Anderson E.J., Kypson A.P., Rodriguez E., et al. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009, 54:1891.
10. Anderson E.J., Rodriguez E., Anderson C.A., et al. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol 2011, 300(1):H118-H124.
11. Colman R.J., Anderson R.M., Johnson S.C., et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201.
12. Scheuermann-Freestone M., Madsen P.L., Manners D., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040.
13. Diamant M., Lamb H.J., Groeneveld Y., et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003, 42:328.
14. Casademont J., Miro O. Electron transport chain defects in heart failure. Heart Fail Rev 2002, 7:131.
15. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190.
16. Peterson L.R., Herrero P., Schechtman K.B., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191.
17. Boudina S., Sena S., O'Neill B.T., et al. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 2005, 112:2686.
18. Boudina S., Sena S., Theobald H., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56:2457.
19. Mazumder P.K., O'Neill B.T., Roberts M.W., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004, 53:2366.
20. Kuo T.H., Moore K.H., Giacomelli F., et al. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes 1983, 32:781.
21. Bugger H., Abel E.D. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009, 2:454.
22. Howarth F.C., Qureshi M.A., Sobhy Z.H., et al. Structural lesions and changing pattern of expression of genes encoding cardiac muscle proteins are associated with ventricular myocyte dysfunction in type 2 diabetic Goto-Kakizaki rats fed a high-fat diet. Exp Physiol 2011, 96:765.
23. Minamiyama Y., Bito Y., Takemura S., et al. Calorie restriction improves cardiovascular risk factors via reduction of mitochondrial reactive oxygen species in type II diabetic rats. J Pharmacol Exp Ther 2007, 320:535.
24. Oliveira P.J., Seica R., Santos D.L., et al. Vitamin E or coenzyme Q10 administration is not fully advantageous for heart mitochondrial function in diabetic goto kakizaki rats. Mitochondrion 2004, 3:337.
25. Buchanan J., Mazumder P.K., Hu P., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341.
26. Aoyama T., Peters J.M., Iritani N., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998, 273:5678.
27. Campbell F.M., Kozak R., Wagner A., et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002, 277:4098.
28. Bugger H., Chen D., Riehle C., et al. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 2009, 58:1986.
29. Finck B.N., Lehman J.J., Leone T.C., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121.
30. Sharma S., Adrogue J.V., Golfman L., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:1692.
31. Turko I.V., Li L., Aulak K.S., et al. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J Biol Chem 2003, 278:33972.
32. Chiu H.C., Kovacs A., Ford D.A., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001, 107:813.
33. Zhou Y.T., Grayburn P., Karim A., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000, 97:1784.
34. Bugger H., Abel E.D. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci (Lond) 2008, 114:195.
35. Morrow D.A., Givertz M.M. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005, 112:3218.
36. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787.
37. Yamagishi S.I., Edelstein D., Du X.L., et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001, 276:25096.
38. Esposito L.A., Melov S., Panov A., et al. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999, 96:4820.
39. Wallace D.C. Mitochondrial genetics: a paradigm for aging and degenerative diseases?. Science 1992, 256:628.
40. Lashin O.M., Szweda P.A., Szweda L.I., et al. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med 2006, 40:886.
41. Shen X., Zheng S., Metreveli N.S., et al. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798.
42. Ye G., Metreveli N.S., Donthi R.V., et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004, 53:1336.
43. Conti M., Renaud I.M., Poirier B., et al. High levels of myocardial antioxidant defense in aging nondiabetic normotensive Zucker obese rats. Am J Physiol Regul Integr Comp Physiol 2004, 286:R793.
44. Santos D.L., Palmeira C.M., Seica R., et al. Diabetes and mitochondrial oxidative stress: a study using heart mitochondria from the diabetic Goto-Kakizaki rat. Mol Cell Biochem 2003, 246:163.
45. Vincent H.K., Powers S.K., Stewart D.J., et al. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Metab Disord 1999, 23:67.
46. Isenberg G., Han S., Schiefer A., et al. Changes in mitochondrial calcium concentration during the cardiac contraction cycle. Cardiovasc Res 1993, 27:1800.
47. Denton R.M., Randle P.J., Martin B.R. Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J 1972, 128:161.
48. Nichols B.J., Denton R.M. Towards the molecular basis for the regulation of mitochondrial dehydrogenases by calcium ions. Mol Cell Biochem 1995, 149-150:203.
49. Territo P.R., Mootha V.K., French S.A., et al. Ca(2+) activation of heart mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase. Am J Physiol Cell Physiol 2000, 278:C423.
50. Flarsheim C.E., Grupp I.L., Matlib M.A. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol 1996, 271:H192.
51. Pierce G.N., Dhalla N.S. Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol 1985, 1:48.
52. Belke D.D., Dillmann W.H. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004, 6:424.
53. Bouchard R.A., Bose D. Influence of experimental diabetes on sarcoplasmic reticulum function in rat ventricular muscle. Am J Physiol 1991, 260:H341.
54. Oliveira P.J., Seica R., Coxito P.M., et al. Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 2003, 554:511.
55. Dong F., Zhang X., Yang X., et al. Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. J Endocrinol 2006, 188:25.
56. Fauconnier J., Lanner J.T., Zhang S.J., et al. Insulin and inositol 1,4,5-trisphosphate trigger abnormal cytosolic Ca2+ transients and reveal mitochondrial Ca2+ handling defects in cardiomyocytes of ob/ob mice. Diabetes 2005, 54:2375.
57. Belke D.D., Swanson E.A., Dillmann W.H. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004, 53:3201.
58. Belke D.D., Betuing S., Tuttle M.J., et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002, 109:629.
59. Boudina S., Bugger H., Sena S., et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009, 119:1272.
60. Bugger H., Riehle C., Jaishy B., et al. Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Mol Cell Cardiol 2012, 52(5):1019-1026.
61. Smith R.A., Porteous C.M., Coulter C.V., et al. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999, 263:709.
62. Jauslin M.L., Meier T., Smith R.A., et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003, 17:1972.
63. Kelso G.F., Porteous C.M., Coulter C.V., et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001, 276:4588.
64. Ross M.F., Prime T.A., Abakumova I., et al. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J 2008, 411:633.
65. Smith R.A., Porteous C.M., Gane A.M., et al. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci U S A 2003, 100:5407.
66. Davidson S.M., Yellon D.M., Murphy M.P., et al. Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res 2012, 93:445.
67. Vergeade A., Mulder P., Vendeville-Dehaudt C., et al. Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ. Free Radic Biol Med 2010, 49:748.
68. Supinski G.S., Murphy M.P., Callahan L.A. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1095.
69. Adlam V.J., Harrison J.C., Porteous C.M., et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005, 19:1088.
70. Rodriguez-Cuenca S., Cocheme H.M., Logan A., et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 2010, 48:161.
71. Dhanasekaran A., Kotamraju S., Kalivendi S.V., et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem 2004, 279:37575.
72. Mao G., Kraus G.A., Kim I., et al. Effect of a mitochondria-targeted vitamin E derivative on mitochondrial alteration and systemic oxidative stress in mice. Br J Nutr 2011, 106:87.
73. Mao G., Kraus G.A., Kim I., et al. A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice. J Nutr 2010, 140:1425.
74. Gane E.J., Weilert F., Orr D.W., et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010, 30:1019.
75. Frantz M.C., Wipf P. Mitochondria as a target in treatment. Environ Mol Mutagen 2010, 51:462.
76. Sheu S.S., Nauduri D., Anders M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 2006, 1762:256.
77. Trnka J., Blaikie F.H., Logan A., et al. Antioxidant properties of MitoTEMPOL and its hydroxylamine. Free Radic Res 2009, 43:4.
78. Dai D.F., Chen T., Szeto H., et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 2011, 58:73.
79. Bantle J.P., Wylie-Rosett J., Albright A.L., et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008, 31(Suppl 1):S61.
80. Cohen H.Y., Miller C., Bitterman K.J., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390.
81. 2 production and oxidative damage. Cardiovasc Res 2007, 74:456.
82. Gredilla R., Sanz A., Lopez-Torres M., et al. Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. FASEB J 2001, 15:1589.
83. Shinmura K., Tamaki K., Sano M., et al. Caloric restriction primes mitochondria for ischemic stress by deacetylating specific mitochondrial proteins of the electron transport chain. Circ Res 2011, 109:396.
84. Viljanen A.P., Karmi A., Borra R., et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol 2009, 103:1721.
85. Hammer S., Snel M., Lamb H.J., et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008, 52:1006.
86. Baur J.A., Pearson K.J., Price N.L., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337.
87. Brasnyo P., Molnar G.A., Mohas M., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011, 106:383.
88. Xu Y., Nie L., Yin Y.G., et al. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol 2012, 259(3):395-401.
89. Danz E.D., Skramsted J., Henry N., et al. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009, 46:1589.
90. Tatlidede E., Sehirli O., Velioglu-Ogunc A., et al. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 2009, 43:195.
91. Sulaiman M., Matta M.J., Sunderesan N.R., et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2010, 298:H833.
92. Xi J., Wang H., Mueller R.A., et al. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur J Pharmacol 2009, 604:111.
93. Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 2011, 1812:1477.
94. Lagouge M., Argmann C., Gerhart-Hines Z., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109.
95. Aasum E., Belke D.D., Severson D.L., et al. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 2002, 283:H949.
96. Aasum E., Khalid A.M., Gudbrandsen O.A., et al. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 2008, 44:201.
97. How O.J., Larsen T.S., Hafstad A.D., et al. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 2007, 113:211.
98. Carley A.N., Semeniuk L.M., Shimoni Y., et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 2004, 286:E449.
99. Brunmair B., Staniek K., Gras F., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052.
100. Nadanaciva S., Dykens J.A., Bernal A., et al. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007, 223:277.
101. Soller M., Drose S., Brandt U., et al. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Mol Pharmacol 2007, 71:1535.
102. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256.
103. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191.
104. Yamada Y., Akita H., Kamiya H., et al. MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim Biophys Acta 2008, 1778:423.
105. Yamada Y., Furukawa R., Yasuzaki Y., et al. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol Ther 2011, 19:1449.
106. Yamada Y., Harashima H. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials 2012, 33:1589.